A novel approach to directly observed therapy for tuberculosis in an HIV-endemic area

American Journal of Public Health

Volumn 91, Issue 1, 2001, Pages 138-141

  Desvarieux, M ^a   Hyppolite, P R ^a   Johnson W D , Jr ^a   Pape, J W ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; PYRAZINAMIDE; PYRIDOXINE; RIFAMPICIN;

ARTICLE; HAITI; HEALTH BEHAVIOR; HEALTH CARE COST; HEALTH CARE DELIVERY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; SHORT COURSE THERAPY;

EID: 0035160266     PISSN: 00900036     EISSN: None     Source Type: Journal    
DOI: 10.2105/AJPH.91.1.138     Document Type: Article

References (29)

1. Control of tuberculosis in the United States
2. Initial therapy for tuberculosis in the era of multidrug resistance: Recommendations of the Advisory Council for the Elimination of Tuberculosis
3. Compliance with tuberculosis therapy
4. Tuberculosis: Commentary on a reemergent killer
5. When tuberculosis treatment fails: A social behavioral account for patient adherence
6. Defaulting from tuberculosis treatment at the Addis Ababa tuberculosis centre and factors associated with it
7. Factors determining compliance in hypertensive patients
8. Determinants of compliance: The disease and the mechanics of treatment
9. HIV and AIDS in Haiti: Recent developments
10. Diagnostic standards and classification of tuberculosis
11. Isoniazid reduces the development of active tuberculosis and delays the progression of HIV infection
12. The supply of antituberculosis drugs: Price evolution
13. Treatment of tuberculosis and tuberculosis infection in adults and children
14. High-compliance tuberculosis treatment program in a rural community
15. Six-month supervised intermittent therapy in Haitian patients with and without HIV infection
16. Tuberculosis in New York City - Turning the tide
17. Tuberculosis treatment is expensive for patients in developing countries
18. World Development Report 1993: Investing in Health
19. Drug-resistant tuberculosis
20. La tuberculose fait de la resistance
21. Beyond four drugs: Health policy and the treatment of the individual patient with tuberculosis
22. Treatment of tuberculosis
23. Directly observed therapy and treatment completion in the United States: Is universal supervised therapy necessary?
24. Bayer and Desvarieux respond